Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2022 Dec;27(12):915-916.
doi: 10.1111/nep.14124. Epub 2022 Oct 22.

Complementary actions of finerenone and SGLT2-i on renal outcomes?: An urgent need for more information

Eleni Rebelos  1   2 , Nikolaos Tentolouris  3
Affiliations
Editorial

Complementary actions of finerenone and SGLT2-i on renal outcomes?: An urgent need for more information

Eleni Rebelos et al. Nephrology (Carlton). 2022 Dec.
No abstract available

PubMed Disclaimer

Conflict of interest statement

The authors declare no potential conflict of interest.

Comment on

References

    1. De Nicola L, Cozzolino M, Genovesi S, Gesualdo L, Grandaliano G, Pontremoli R. Can SGLT2 inhibitors answer unmet therapeutic needs in chronic kidney disease? J Nephrol. 2022;35:1605‐1618. doi:10.1007/s40620-022-01336-7 - DOI - PMC - PubMed
    1. Filippatos G, Anker SD, Agarwal R, et al. Finerenone reduces risk of incident heart failure in patients with chronic kidney disease and type 2 diabetes: analyses from the FIGARO‐DKD trial. Circulation. 2022;145:437‐447. doi:10.1161/CIRCULATIONAHA.121.057983 - DOI - PMC - PubMed
    1. Bakris GL, Agarwal R, Anker SD, et al. Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes. N Engl J Med. 2020;383:2219‐2229. doi:10.1056/NEJMoa2025845 - DOI - PubMed
    1. Kolkhof P, Hartmann E, Freyberger A, et al. Effects of finerenone combined with empagliflozin in a model of hypertension‐induced end‐organ damage. Am J Nephrol. 2021;52:642‐652. doi:10.1159/000516213 - DOI - PMC - PubMed
    1. Provenzano M, Puchades MJ, Garofalo C, et al. Albuminuria‐lowering effect of dapagliflozin, eplerenone, and their combination in patients with chronic kidney disease: a randomized crossover clinical trial. J Am Soc Nephrol. 2022;33:1569‐1580. doi:10.1681/ASN.2022020207 - DOI - PMC - PubMed